Cargando…
Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge
Layer-by-layer microparticle (LbL-MP) fabrication was used to produce synthetic vaccines presenting a fusion peptide containing RSV G protein CX3C chemokine motif and a CD8 epitope of the RSV matrix protein 2 (GM2) with or without a covalently linked TLR2 agonist (Pam3.GM2). Immunization of BALB/c m...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785538/ https://www.ncbi.nlm.nih.gov/pubmed/36560488 http://dx.doi.org/10.3390/vaccines10122078 |
_version_ | 1784858073184075776 |
---|---|
author | Powell, Thomas J. Jacobs, Andrea Tang, Jie Cardenas, Edwin Palath, Naveen Daniels, Jennifer Boyd, James G. Bergeron, Harrison C. Jorquera, Patricia A. Tripp, Ralph A. |
author_facet | Powell, Thomas J. Jacobs, Andrea Tang, Jie Cardenas, Edwin Palath, Naveen Daniels, Jennifer Boyd, James G. Bergeron, Harrison C. Jorquera, Patricia A. Tripp, Ralph A. |
author_sort | Powell, Thomas J. |
collection | PubMed |
description | Layer-by-layer microparticle (LbL-MP) fabrication was used to produce synthetic vaccines presenting a fusion peptide containing RSV G protein CX3C chemokine motif and a CD8 epitope of the RSV matrix protein 2 (GM2) with or without a covalently linked TLR2 agonist (Pam3.GM2). Immunization of BALB/c mice with either GM2 or Pam3.GM2 LbL-MP in the absence of adjuvant elicited G-specific antibody responses and M2-specific CD8+ T-cell responses. Following challenge with RSV, mice immunized with the GM2 LbL-MP vaccine developed a Th2-biased immune response in the lungs with elevated levels of IL-4, IL-5, IL-13, and eotaxin in the bronchoalveolar lavage (BAL) fluid and a pulmonary influx of eosinophils. By comparison, mice immunized with the Pam3.GM2 LbL-MP vaccine had considerably lower to non-detectable levels of the Th2 cytokines and chemokines and very low numbers of eosinophils in the BAL fluid post-RSV challenge. In addition, mice immunized with the Pam3.GM2 LbL-MP also had higher levels of RSV G-specific IgG2a and IgG2b in the post-challenge BAL fluid compared to those immunized with the GM2 LbL-MP vaccine. While both candidates protected mice from infection following challenge, as evidenced by the reduction or elimination of RSV plaques, the inclusion of the TLR2 agonist yielded a more potent antibody response, greater protection, and a clear shift away from Th2/eosinophil responses. Since the failure of formalin-inactivated RSV (FI-RSV) vaccines tested in the 1960s has been hypothesized to be partly due to the ablation of host TLR engagement by the vaccine and inappropriate Th2 responses upon subsequent viral infection, these findings stress the importance of appropriate engagement of the innate immune response during initial exposure to RSV G CX3C. |
format | Online Article Text |
id | pubmed-9785538 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97855382022-12-24 Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge Powell, Thomas J. Jacobs, Andrea Tang, Jie Cardenas, Edwin Palath, Naveen Daniels, Jennifer Boyd, James G. Bergeron, Harrison C. Jorquera, Patricia A. Tripp, Ralph A. Vaccines (Basel) Article Layer-by-layer microparticle (LbL-MP) fabrication was used to produce synthetic vaccines presenting a fusion peptide containing RSV G protein CX3C chemokine motif and a CD8 epitope of the RSV matrix protein 2 (GM2) with or without a covalently linked TLR2 agonist (Pam3.GM2). Immunization of BALB/c mice with either GM2 or Pam3.GM2 LbL-MP in the absence of adjuvant elicited G-specific antibody responses and M2-specific CD8+ T-cell responses. Following challenge with RSV, mice immunized with the GM2 LbL-MP vaccine developed a Th2-biased immune response in the lungs with elevated levels of IL-4, IL-5, IL-13, and eotaxin in the bronchoalveolar lavage (BAL) fluid and a pulmonary influx of eosinophils. By comparison, mice immunized with the Pam3.GM2 LbL-MP vaccine had considerably lower to non-detectable levels of the Th2 cytokines and chemokines and very low numbers of eosinophils in the BAL fluid post-RSV challenge. In addition, mice immunized with the Pam3.GM2 LbL-MP also had higher levels of RSV G-specific IgG2a and IgG2b in the post-challenge BAL fluid compared to those immunized with the GM2 LbL-MP vaccine. While both candidates protected mice from infection following challenge, as evidenced by the reduction or elimination of RSV plaques, the inclusion of the TLR2 agonist yielded a more potent antibody response, greater protection, and a clear shift away from Th2/eosinophil responses. Since the failure of formalin-inactivated RSV (FI-RSV) vaccines tested in the 1960s has been hypothesized to be partly due to the ablation of host TLR engagement by the vaccine and inappropriate Th2 responses upon subsequent viral infection, these findings stress the importance of appropriate engagement of the innate immune response during initial exposure to RSV G CX3C. MDPI 2022-12-05 /pmc/articles/PMC9785538/ /pubmed/36560488 http://dx.doi.org/10.3390/vaccines10122078 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Powell, Thomas J. Jacobs, Andrea Tang, Jie Cardenas, Edwin Palath, Naveen Daniels, Jennifer Boyd, James G. Bergeron, Harrison C. Jorquera, Patricia A. Tripp, Ralph A. Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge |
title | Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge |
title_full | Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge |
title_fullStr | Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge |
title_full_unstemmed | Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge |
title_short | Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge |
title_sort | microparticle rsv vaccines presenting the g protein cx3c chemokine motif in the context of tlr signaling induce protective th1 immune responses and prevent pulmonary eosinophilia post-challenge |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785538/ https://www.ncbi.nlm.nih.gov/pubmed/36560488 http://dx.doi.org/10.3390/vaccines10122078 |
work_keys_str_mv | AT powellthomasj microparticlersvvaccinespresentingthegproteincx3cchemokinemotifinthecontextoftlrsignalinginduceprotectiveth1immuneresponsesandpreventpulmonaryeosinophiliapostchallenge AT jacobsandrea microparticlersvvaccinespresentingthegproteincx3cchemokinemotifinthecontextoftlrsignalinginduceprotectiveth1immuneresponsesandpreventpulmonaryeosinophiliapostchallenge AT tangjie microparticlersvvaccinespresentingthegproteincx3cchemokinemotifinthecontextoftlrsignalinginduceprotectiveth1immuneresponsesandpreventpulmonaryeosinophiliapostchallenge AT cardenasedwin microparticlersvvaccinespresentingthegproteincx3cchemokinemotifinthecontextoftlrsignalinginduceprotectiveth1immuneresponsesandpreventpulmonaryeosinophiliapostchallenge AT palathnaveen microparticlersvvaccinespresentingthegproteincx3cchemokinemotifinthecontextoftlrsignalinginduceprotectiveth1immuneresponsesandpreventpulmonaryeosinophiliapostchallenge AT danielsjennifer microparticlersvvaccinespresentingthegproteincx3cchemokinemotifinthecontextoftlrsignalinginduceprotectiveth1immuneresponsesandpreventpulmonaryeosinophiliapostchallenge AT boydjamesg microparticlersvvaccinespresentingthegproteincx3cchemokinemotifinthecontextoftlrsignalinginduceprotectiveth1immuneresponsesandpreventpulmonaryeosinophiliapostchallenge AT bergeronharrisonc microparticlersvvaccinespresentingthegproteincx3cchemokinemotifinthecontextoftlrsignalinginduceprotectiveth1immuneresponsesandpreventpulmonaryeosinophiliapostchallenge AT jorquerapatriciaa microparticlersvvaccinespresentingthegproteincx3cchemokinemotifinthecontextoftlrsignalinginduceprotectiveth1immuneresponsesandpreventpulmonaryeosinophiliapostchallenge AT trippralpha microparticlersvvaccinespresentingthegproteincx3cchemokinemotifinthecontextoftlrsignalinginduceprotectiveth1immuneresponsesandpreventpulmonaryeosinophiliapostchallenge |